Vicus Therapeutics is a private biopharmaceutical company dedicated to bringing breakthrough multi-drug treatments to patients with cancer.

Vicus’ lead product, VT-122, is designed to enhance the effectiveness of targeted drug therapies for advanced cancer patients with systemic inflammation. In a Phase 2 study of advanced lung cancer patients, VT-122 demonstrated a statistically significant improvement in lean body mass, an endpoint reflective of systemic inflammation.